Analyzing liver tumor tissue after ablation to guide further treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect and analyze needle biopsy samples from liver metastases following a tumor ablation procedure. By identifying any remaining cancer cells in these samples, the study seeks to inform subsequent treatment decisions for patients. The methodology involves using metabolic imaging and predictive genetic signatures to optimize treatment strategies. The study will assess the effectiveness of these approaches in improving patient outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of liver metastases from various primary tumors
* Confined liver disease or limited extrahepatic disease stable/controlled for at least 4 months (extrahepatic disease amenable to treatment is allowed)
* Lesions of ≤3 cm in maximum diameter
* At least one FDG-avid lesion to be treated\*\*\*
* INR \< 1.5\*
* Platelet count ≥ 50,000

Exclusion Criteria:

* Age \< 18
* Less than 5 mm distance to a structure (GI or biliary tract), that cannot be protected from ablation injury with technical modifications such as hydro or air dissection
* INR \> 1.5 that cannot be corrected with fresh frozen plasma \*\*
* Platelet count of \<50,000 that cannot be corrected with transfusion
* More than 3 tumors in the liver
* More than 5 tumors of extrahepatic disease (including mediastinal nodes and pulmonary nodules, abdominal or other lymph nodes, and bone metastasis)
* Presence of any peritoneal Carcinomatosis

  * For patients on Coumadin, general clinical guidelines for IR ablation will be followed.

    * For patients with no FDG-PET avid tumors aim 2 of the protocol will not be assessed

Where it's running

• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Constantinos Sofocleous, MD, PhD — Memorial Sloan Kettering Cancer Center
• Study coordinator: Constantinos Sofocleous, MD, PhD
• Email: sofoclec@mskcc.org
• Phone: 212-639-3379

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Prospective look at liver metastases imaging and tissue patterns in colorectal and breast cancer

  This observational study tests whether 3D maps of histopathological growth patterns in liver metastases align with imaging features from MRI/CT in patients undergoing liver surgery.

  Recruiting Cancer Research Antwerp · Wilrijk, Antwerp · NCT07781306

• Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

  Doctors are testing whether adding vascular deformation mapping to CT measurements can better predict liver failure after removing a large portion of the liver.

  Recruiting at 3 sites Minia University · Minya, Minya Governorate and 2 other locations · NCT07727759

• DRAGON: International registry for patients who had combined portal and hepatic vein embolization before liver surgery

  This registry collects data on patients who had PVE/HVE before liver resection to see if it helps liver regeneration and what factors relate to outcomes.

  Recruiting at 30 sites Maastricht University Medical Center · Chicago, Illinois and 30 other locations · NCT07717437

• Metastatic liver cancer patient registry from multiple Chinese centers

  This is a registry that collects real-world data on adults with liver metastases to understand patterns and prognosis and to support future research.

  Recruiting at 2 sites Anhui Provincial Hospital · Bengbu, Anhui and 2 other locations · NCT07602504

• HEPZATO KIT with Opdualag for metastatic melanoma that has spread to the liver

  This will try adding HEPZATO KIT to Opdualag (nivolumab + relatlimab) to see if it's safe and helps people with metastatic melanoma that has spread to the liver.

  Recruiting Phase 1/2 University of Wisconsin, Madison · Madison, Wisconsin · NCT07281924

• Neoadjuvant immunotherapy with Dupilumab and Toripalimab for MSS colorectal cancer with resectable liver metastases

  This study tests a pre-surgery treatment combining dupilumab and toripalimab in adults with microsatellite-stable colorectal cancer that has liver metastases, to see if it’s safe and can lead to major tumor response.

  Recruiting Phase 1/2 Icahn School of Medicine at Mount Sinai · New York, New York · NCT07277322

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.